Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $21.10 and last traded at $21.3750, with a volume of 124561 shares. The stock had previously closed at $19.69.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Chardan Capital boosted their target price on Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Robert W. Baird boosted their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. BTIG Research upped their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group lifted their price target on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and an average target price of $26.50.

Alto Neuroscience Price Performance

The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $665.83 million, a price-to-earnings ratio of -9.36 and a beta of 2.52. The company has a fifty day moving average price of $17.28 and a two-hundred day moving average price of $12.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $62,000. Balyasny Asset Management L.P. acquired a new position in Alto Neuroscience in the 4th quarter valued at about $198,000. Bank of Montreal Can purchased a new stake in Alto Neuroscience during the 2nd quarter valued at approximately $25,000. OMERS ADMINISTRATION Corp acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $221,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after acquiring an additional 2,055 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.